CRDL

Cardiol Therapeutics Inc.

1.75 USD
+0.03 (+1.74%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cardiol Therapeutics Inc. stock is up 27.74% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 February’s closed higher than January.

About Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc. focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD) Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study. The company is also developing a proprietary subcutaneous formulation of cannabidiol to achieve higher bioavailability.